NCT07346573Completed
Radiotherapy Safety for Liver Malignancies Using Post-Treatment Imaging
A Retrospective Single-Center Study Utilizing AI-Based Radiomics on Pre- and Post-Radiotherapy CT Images to Explore the Safety Dose Threshold in Liver Malignancy Radiation Therapy
Source: ClinicalTrials.gov · Last updated 16 Jan 2026
Brief summary (registry, in English)
The goal of this retrospective observational study is to investigate the safety of radiation therapy for liver malignancies by analyzing data from patients who have already completed this treatment . The main questions it aims to answer are: What is the specific radiation dose level that leads to a visible change on CT scans called a Focal Liver Reaction (FLR)? Why do some patients develop these imaging changes while others do not, based on their scan features and clinical information? Researchers will compare patients who developed FLR with those who did not to identify the factors associated with this reaction. This study uses existing medical records and images; therefore, participants will not need to undergo any new interventions or procedures.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 274 (actual)
- First submitted
- 15 Dec 2025
- Start date
- May 2019
- Primary completion date
- Mar 2025
- Lead sponsor
- Cao peiguo
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT07346573
What you commit to
- Study type: Observational
- Participants enrolled: 274
- From May 2019 to the primary completion date, Mar 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of upper abdominal radiotherapy or liver transplantation.
- Failure to complete radiotherapy as scheduled.
- Previous cancer treatment-related toxicities that did not return to baseline or grade 0-1 (except for hair loss and peripheral neuropathy).
Who the study is looking for
- Primary or secondary liver malignancies, including hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), and secondary liver tumors.
- Liver function of Child-Pugh classification A or B.
- Completed EBRT treatment as planned.
- No other local treatment of liver lesions between EBRT and the follow-up imaging examination.
- Complete imaging re-examination data.
- Three-phase enhancement CT scans showing typical Focal Liver Reaction (FLR).
- The registration effect of follow-up CT and planning CT is satisfactory.
Age in the registry: 18 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Third Xiangya Hospital Coordinator of this site? Confirm its status | Changsha | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.